Change of Adviser

RNS Number : 8677X

Stem Cell Sciences plc

30 June 2008

 



Stem Cell ScienceS 

("Stem Cell Sciences", "SCS")

CHANGE OF ADVISER

Date 30 June 2008

Stem Cell Sciences plc (AIM:STEM, ASX:STC), a leading provider of cells and cell culture media to the global pharmaceutical, biopharmaceutical and research markets, announced today that with immediate effect it has appointed Daniel Stewart & Company plc as its Nominated Adviser and Broker.

ENDS

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)

Giorgio Reggiani (Company Secretary) 

[phone]

Daniel Stewart & Company plc

Simon Leathers, Simon Starr                

[phone]

Halsin Partners (United Kingdom)

Michael Sinclair, Director

[phone]

Talk Biotech (Australia)

Fay Weston, Director

[phone]

Notes to Editors

Stem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) specialises in developing and commercialising technologies to grow, differentiate and purify embryonic, neural and other tissue-specific stem cells. Our patented technologies, proprietary cells, and automated processes and services provide pharmaceutical and biotechnology companies with industrial-scale resources to accelerate drug discovery programmes and regenerative medicine therapies.

Stem Cell Sciences has multiple industry collaborations, including Millipore Corporation for the marketing and distribution of HEScGRO™, its serum free media for the growth of human embryonic stem cells, Merck & Co for the use of mouse neural stem cell technology for research applications and a collaboration in diabetes research with a major pharmaceutical company.

The company is headquartered in Cambridge, UK, in a new, fully equipped cell culture facility featuring state of the art automation for cell culture, with business offices in California (USA) and a research operation in Australia. For further information on the company please visit:  www.stemcellsciences.com.

 

END

 

 

APPFBLFXVQBLBBD